Search

Your search keyword '"Duarte, PAD"' showing total 2 results
Start Over Author "Duarte, PAD" Topic influenza, human
2 results on '"Duarte, PAD"'

1. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.

Author

Venkatesan S, Myles PR, Bolton KJ, Muthuri SG, Al Khuwaitir T, Anovadiya AP, Azziz-Baumgartner E, Bajjou T, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Chinbayar T, Cilloniz C, Denholm JT, Dominguez SR, Duarte PAD, Dubnov-Raz G, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Higuera Iglesias AL, Hoeger PH, Hu XY, Islam QT, Jiménez MF, Keijzers G, Khalili H, Kusznierz G, Kuzman I, Langenegger E, Lankarani KB, Leo YS, Libster RP, Linko R, Madanat F, Maltezos E, Mamun A, Manabe T, Metan G, Mickiene A, Mikić D, Mohn KGI, Oliva ME, Ozkan M, Parekh D, Paul M, Rath BA, Refaey S, Rodríguez AH, Sertogullarindan B, Skręt-Magierło J, Somer A, Talarek E, Tang JW, To K, Tran D, Uyeki TM, Vaudry W, Vidmar T, Zarogoulidis P, and Nguyen-Van-Tam JS

Subjects
Adolescent, Adrenal Cortex Hormones therapeutic use, Adult, Aged, Anti-Bacterial Agents therapeutic use, Child, Enzyme Inhibitors pharmacology, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult, Antiviral Agents therapeutic use, Enzyme Inhibitors therapeutic use, Influenza A Virus, H1N1 Subtype, Influenza, Human drug therapy, Influenza, Human epidemiology, Length of Stay, Neuraminidase antagonists & inhibitors, Pandemics
Abstract

Background: The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear., Methods: We conducted a one-stage individual participant data (IPD) meta-analysis exploring the association between NAI treatment and LoS in patients hospitalized with 2009 influenza A(H1N1) virus (A[H1N1]pdm09) infection. Using mixed-effects negative binomial regression and adjusting for the propensity to receive NAI, antibiotic, and corticosteroid treatment, we calculated incidence rate ratios (IRRs) and 95% confidence intervals (CIs). Patients with a LoS of <1 day and those who died while hospitalized were excluded., Results: We analyzed data on 18 309 patients from 70 clinical centers. After adjustment, NAI treatment initiated at hospitalization was associated with a 19% reduction in the LoS among patients with clinically suspected or laboratory-confirmed influenza A(H1N1)pdm09 infection (IRR, 0.81; 95% CI, .78-.85), compared with later or no initiation of NAI treatment. Similar statistically significant associations were seen in all clinical subgroups. NAI treatment (at any time), compared with no NAI treatment, and NAI treatment initiated <2 days after symptom onset, compared with later or no initiation of NAI treatment, showed mixed patterns of association with the LoS., Conclusions: When patients hospitalized with influenza are treated with NAIs, treatment initiated on admission, regardless of time since symptom onset, is associated with a reduced LoS, compared with later or no initiation of treatment., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)

Published
2020
Full Text
View/download PDF

2. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data

Author

Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Al Khuwaitir, TSA, Al Mamun, A, Anovadiya, AP, Azziz-Baumgartner, E, Báez, C, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, VH, Burgmann, H, Cao, B, Carratala, J, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Echavarria, M, Fanella, S, Gao, Z, Gérardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoger, PH, Hu, X, Islam, QT, Jiménez, MF, Kandeel, A, Keijzers, G, Khalili, H, Knight, M, Kudo, K, Kusznierz, G, Kuzman, I, Kwan, AMC, Amine, IL, Langenegger, E, Lankarani, KB, Leo, Y-S, Linko, R, Liu, P, Madanat, F, Mayo-Montero, E, McGeer, A, Memish, Z, Metan, G, Mickiene, A, Mikic, D, Mohn, KGI, Moradi, A, Nymadawa, P, Oliva, ME, Ozkan, M, Parekh, D, Paul, M, Polack, FP, Rath, BA, Rodríguez, AH, Sarrouf, EB, Seale, AC, Sertogullarindan, B, Siqueira, MM, Skret-Magierlo, J, Stephan, F, Talarek, E, Tang, JW, To, KKW, Torres, A, Törün, SH, Tran, D, Uyeki, TM, van Zwol, A, Vaudry, W, Vidmar, T, Yokota, RTC, Zarogoulidis, P, Nguyen-van-Tam, JS, Aguiar-Oliveira, ML, Al Masri, M, Amin, R, Araújo, WN, Ballester-Orcal, E, Bantar, C, Bao, J, Barhoush, MM, Basher, A, Bautista, E, Bettinger, J, Bingisser, R, Bouza, E, Bozkurt, I, Celjuska-Tošev, E, Chan, KKC, Chen, Y, Chinbayar, T, Cilloniz, C, Cox, RJ, Cuezzo, MR, Cui, W, Dashti-Khavidaki, S, du, B, El Rhaffouli, H, Escobar, H, Florek-Michalska, A, Fraser, J, Gerrard, J, Gormley, S, Götberg, S, Hoffmann, M, Honarvar, B, Hu, J, Kemen, C, Khandaker, G, Koay, KSC, Kojic, M, Kyaw, WM, Leibovici, L, Li, H, Li, X-L, Libster, R, Loh, TP, Macbeth, D, Maltezos, E, Manabe, T, Marcone, DN, Marczynska, M, Mastalir, FP, Moghadami, M, Moriconi, L, Ozbay, B, Pečavar, B, Poeppl, W, Poliquin, PG, Rahman, M, Rascon-Pacheco, A, Refaey, S, Schweiger, B, Smith, FG, Somer, A, Souza, TML, Tabarsi, P, Tripathi, CB, Velyvyte, D, Viasus, D, Yu, Q, Yuen, K-Y, Zhang, W, Zuo, W, Pediatric surgery, CCA - Innovative therapy, Muthuri, Stella G., Venkatesan, Sudhir, Myles, Puja R., Leonardi-Bee, Jo, Al Khuwaitir, Tarig S. A., Al Mamun, Adbullah, Anovadiya, Ashish P., Azziz-Baumgartner, Eduardo, Báez, Clarisa, Bassetti, Matteo, Beovic, Bojana, Bertisch, Barbara, Bonmarin, Isabelle, Booy, Robert, Borja-Aburto, Victor H., Burgmann, Heinz, Cao, Bin, Carratala, Jordi, Denholm, Justin T., Dominguez, Samuel R., Duarte, Pericles A.D., Dubnov-Raz, Gal, Echavarria, Marcela, Fanella, Sergio, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath L., Hoger, Peter H., Hu, Xiaoyun, Islam, Quazi T., Jiménez, Mirela F., Kandeel, Amr, Keijzers, Gerben, Khalili, Hossein, Knight, Marian, Kudo, Koichiro, Kusznierz, Gabriela, Kuzman, Ilija, Kwan, Arthur M. C., Amine, Idriss Lahlou, Langenegger, Eduard, Lankarani, Kamran B., Leo, Yee-Sin, Linko, Rita, Liu, Pei, Madanat, Fari, Mayo-Montero, Elga, Mcgeer, Allison, Memish, Ziad, Metan, Gokhan, Mickiene, Aukse, Mikic, Dragan, Mohn, Kristin G.I., Moradi, Ahmadreza, Nymadawa, Pagbajabyn, Oliva, Maria E., Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Polack, Fernando P., Rath, Barbara A., Rodríguez, Alejandro H., Sarrouf, Elena B., Seale, Anna C., Sertogullarindan, Bunyamin, Siqueira, Marilda M., Skret-Magierlo, Joanna, Stephan, Frank, Talarek, Ewa, Tang, Julian W., To, Kelvin K.W., Torres, Antoni, Törün, Selda H., Tran, Dat, Uyeki, Timothy M., van Zwol, Annelie, Vaudry, Wendy, Vidmar, Tjasa, Yokota, Renata T.C., Zarogoulidis, Paul, Nguyen-van-Tam, Jonathan S, Aguiar-Oliveira, Maria de Lourde, Al Masri, Malakita, Amin, Robed, Araújo, Wildo N., Ballester-Orcal, Elena, Bantar, Carlo, Bao, Jing, Barhoush, Mazen M., Basher, Ariful, Bautista, Edgar, Bettinger, Julie, Bingisser, Roland, Bouza, Emilio, Bozkurt, Ilkay, Celjuska-Tošev, Elvira, Chan, Kenny K.C., Chen, Yusheng, Chinbayar, Tserendorj, Cilloniz, Catia, Cox, Rebecca J., Cuezzo, María R., Cui, Wei, Dashti-Khavidaki, Simin, Du, Bin, El Rhaffouli, Hicham, Escobar, Hernan, Florek-Michalska, Agnieszka, Fraser, Jame, Gerrard, John, Gormley, Stuart, Götberg, Sandra, Hoffmann, Matthia, Honarvar, Behnam, Hu, Jianmin, Kemen, Christoph, Khandaker, Gulam, Koay, Evelyn S. C., Kojic, Miroslav, Kyaw, Win M., Leibovici, Leonard, Li, Hongru, Li, Xiao-Li, Libster, Romina, Loh, Tze P., Macbeth, Deborough, Maltezos, Efstratio, Manabe, Toshie, Marcone, Débora N., Marczynska, Magdalena, Mastalir, Fabiane P., Moghadami, Mohsen, Moriconi, Lilian, Ozbay, Bulent, Pečavar, Blaž, Poeppl, Wolfgang, Poliquin, Philippe G., Rahman, Mahmudur, Rascon-Pacheco, Alberto, Refaey, Samir, Schweiger, Brunhilde, Smith, Fang G., Somer, Ayper, Souza, Thiago M. L., Tabarsi, Payam, Tripathi, Chandrabhanu B., Velyvyte, Daiva, Viasus, Diego, Yu, Qin, Yuen, Kwok-Yung, Zhang, Wei, and Zuo, Wei

Subjects
Male, ANTIVIRAL TREATMENT, IMPACT, Respiratory System, CHILDREN, Neuraminidase inhibitors, Pandemic influenza, Mortality, Meta-analysis, medicine.disease_cause, THERAPY, chemistry.chemical_compound, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, Pandemic, Influenza A Virus, Influenza A virus, Zanamivir, 030212 general & internal medicine, Enzyme Inhibitors, Child, OUTCOMES, 0303 health sciences, biology, Neuraminidase inhibitor, Medicine (all), virus diseases, Middle Aged, 3. Good health, Hospitalization, Treatment Outcome, Female, Life Sciences & Biomedicine, Adolescent, Adult, Antiviral Agents, Humans, Influenza, Human, Neuraminidase, Oseltamivir, Proportional Hazards Models, Young Adult, Pandemics, Pulmonary and Respiratory Medicine, Human, medicine.drug, medicine.medical_specialty, medicine.drug_class, PANDEMIC INFLUENZA, Article, PRIDE Consortium Investigators, 03 medical and health sciences, Critical Care Medicine, General & Internal Medicine, Internal medicine, medicine, H1N1 Subtype, Intensive care medicine, Science & Technology, 030306 microbiology, business.industry, STEM-CELL TRANSPLANTATION, ADULTS, Odds ratio, Influenza, chemistry, RISK-FACTORS, biology.protein, business
Abstract

Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection. Methods: We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identified potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling. Findings: We included data for 29234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0·81; 95% CI 0·70-0·93; p=0·0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0·48; 95% CI 0·41-0·56; p

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results